AUG 27, 2018 1:00 PM PDT

Drug Reduces Deaths and Hospitalization from Heart Failure

WRITTEN BY: Caitlin Williams

Cardiomyopathy is a disease that affects the heart muscles and can potentially lead to heart failure. Cardiomyopathy can be acquired or hereditary and makes it hard for the heart to deliver blood to the body. In the United States alone there are over 200,000 cases per year. Risk factors can include weight, blood pressure, family history, illicit drug use, and other diseases such as diabetes. While you cannot prevent cardiomyopathy in many cases, you can reduce your chance by living a healthy lifestyle consisting of a healthy diet, regular exercises and sleep, and controlling blood pressure or high cholesterol.

There are different types of cardiomyopathy, one of which is typically fatal and called transthyretin amyloid cardiomyopathy (ATTR-CM), once diagnosed patients live an average of three to five years. ATTR-CM destabilizes transthyretin proteins leading to amyloid deposition in the heart, leading to heart and cardiac symptoms. Transthyretin proteins are transport proteins that circulate in the blood; when it becomes unstable and unfolds in ATTR-CM, it can build up in the heart as amyloid fibrils which cause the heart to become stiff.

The disease is most common in men over the age of 60 and can be caused by heritable genetic mutations or changes in the regulation of transthyretin due to age. "ATTR-CM is considered to be a rare disease, but it is underdiagnosed," says Dr. Mathew S. Maurer, the trial’s co-chair and a heart failure specialist at Columbia University Vagelos Colle of Physicians and Surgeons and NewYork-Presbyterian. "Until recently, cardiologists rarely tested for ATTR-CM, because diagnosis required a heart muscle biopsy and there has been no treatment for the disease. But now that we can detect the disease with noninvasive imaging, we're finding more cases."

A recent study published in the New England Journal of Medicine from researchers at Columbia University details a 2 ½ year phase three clinical trial of a drug, tafamidis, that significantly reduces deaths and hospitalization in patients with ATTR-CM. Compared to a placebo tafamidis reduced deaths by 30%, reduced cardiovascular-related hospitalizations by 32%, and slowed decline in quality of life among 441 patients enrolled. Tafamidis works by stabilizing transthyretin by preventing its dissociation and ability to form amyloid, thereby preventing any build up as amyloid fibrils. The drug also slows decline in heart function and quality of life without causing additional adverse effects. However, tafamidis is most effective when given earlier in disease progression rather than later. For most ATTR-CM cases patients are diagnosed with advanced disease, leading to less benefit from tafamidis. Diagnosing patients earlier is key to getting the most significant benefit from the drug.

Currently, the U.S. Food and Drug Administration is considering approval of tafamidis from the treatment of ATTR-CM, but Pfizer has established an early access program at specific sites. "Based on this study, tafamidis may offer the first treatment for patients with this type of heart disease," Maurer says. "Right now, the best we can do is manage the symptoms of ATTR-CM."

To learn more about cardiomyopathy watch the video below!

Sources: New England Journal of Medicine, Mayo Clinic, Pfizer

About the Author
  • Caitlin holds a doctorate degree in Microbiology from the University of Georgia where she studied Mycoplasma pneumoniae and its glycan receptors. She received her Bachelor's in Biology from Virginia Tech (GO HOKIES!). She has a passion for science communication and STEM education with a goal to improve science literacy. She enjoys topics related to human health, with a particular soft spot for pathogens.
You May Also Like
SEP 03, 2020
Cardiology
Does Hypertension Make It Harder to Recognize Others Emotions?
SEP 03, 2020
Does Hypertension Make It Harder to Recognize Others Emotions?
Have you ever felt your blood pressure rise when you get angry or stressed? Well, this phenomenon is unique in that it l ...
SEP 10, 2020
Cardiology
Many Doctors Have Used the Wrong Criteria to Diagnose Hypertension
SEP 10, 2020
Many Doctors Have Used the Wrong Criteria to Diagnose Hypertension
A recent survey has shown that most health care professionals may not be using the current information to screen for and ...
OCT 14, 2020
Immunology
Happiness Linked to Heart Attack Risk
OCT 14, 2020
Happiness Linked to Heart Attack Risk
Asking patients questions about their personal lives could predict their future risk of a heart attack. A study, publish ...
OCT 12, 2020
Cardiology
Pig Hearts Might be Used in Human Transplants by the End of 2021
OCT 12, 2020
Pig Hearts Might be Used in Human Transplants by the End of 2021
A major problem in the transplant field is a lack of healthy donor organs. For many years, scientists in the field of re ...
OCT 22, 2020
Cardiology
Using Liposomes to Deliver Repair Packages to the Heart
OCT 22, 2020
Using Liposomes to Deliver Repair Packages to the Heart
The secret to any successful drug is not just its ability to treat a disease but its ability to target the disease exclu ...
NOV 24, 2020
Cardiology
Patients on Statins Get the 'Nocebo Effect'
NOV 24, 2020
Patients on Statins Get the 'Nocebo Effect'
Millions of people around the world take statins to treat high cholesterol, which are estimated to reduce the risk of he ...
Loading Comments...